Literature DB >> 10756149

Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease.

K M Dobos1, E A Spotts, B J Marston, C R Horsburgh, C H King.   

Abstract

Buruli ulcer (BU) is an emerging necrotic skin disease caused by Mycobacterium ulcerans. To assess the potential for a serodiagnostic test, we measured the humoral immune response of BU patients to M. ulcerans antigens and compared this response with delayed-type hypersensitivity responses to both Burulin and PPD. The delayed-type hypersensitivity response generally supported the diagnosis of BU, with overall reactivity to Burulin in 28 (71.8%) of 39 patients tested, compared with 3 (14%) of 21 healthy controls. However, this positive skin test response was observed primarily in patients with healed or active disease, and rarely in patients with early disease (p=0.009). When tested for a serologic response to M. ulcerans culture filtrate, 43 (70.5%) of 61 BU patients had antibodies to these antigens, compared with 10 (37.0%) of 27 controls and 4 (30. 8%) of 13 tuberculosis patients. There was no correlation between disease stage and the onset of this serum antibody response. Our findings suggest that serologic testing may be useful in the diagnosis and surveillance of BU.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756149      PMCID: PMC2640848          DOI: 10.3201/eid0602.000208

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  20 in total

1.  Insects in the transmission of Mycobacterium ulcerans infection.

Authors:  F Portaels; P Elsen; A Guimaraes-Peres; P A Fonteyne; W M Meyers
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

Review 2.  Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis.

Authors:  A M Dannenberg
Journal:  Immunol Today       Date:  1991-07

Review 3.  Studies on lepromin and soluble antigens of M.leprae: their classification standardization and use.

Authors:  U Sengupta
Journal:  Indian J Lepr       Date:  1991 Jul-Dec

4.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

5.  Multiple skin testing of tuberculosis patients with a range of new tuberculins, and a comparison with leprosy and Mycobacterium ulcerans infection.

Authors:  M J Shield; J L Stanford; R C Paul; J W Carswell
Journal:  J Hyg (Lond)       Date:  1977-06

6.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

Authors:  J H Morrissey
Journal:  Anal Biochem       Date:  1981-11-01       Impact factor: 3.365

Review 9.  Postulated epidemiology of Mycobacterium ulcerans infection.

Authors:  J Hayman
Journal:  Int J Epidemiol       Date:  1991-12       Impact factor: 7.196

Review 10.  An immunogenetic view of delayed type hypersensitivity.

Authors:  R R De Vries
Journal:  Tubercle       Date:  1991-09
View more
  25 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans.

Authors:  Diana Diaz; Heinz Döbeli; Dorothy Yeboah-Manu; Ernestina Mensah-Quainoo; Arno Friedlein; Nicole Soder; Simona Rondini; Thomas Bodmer; Gerd Pluschke
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

3.  Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.

Authors:  Martinha S Oliveira; Alexandra G Fraga; Egídio Torrado; António G Castro; João P Pereira; Adhemar Longatto Filho; Fernanda Milanezi; Fernando C Schmitt; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Authors:  Egídio Torrado; Alexandra G Fraga; António G Castro; Pieter Stragier; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

5.  Mycobacterium ulcerans cytotoxicity in an adipose cell model.

Authors:  K M Dobos; P L Small; M Deslauriers; F D Quinn; C H King
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.

Authors:  A Tanghe; J Content; J P Van Vooren; F Portaels; K Huygen
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

7.  Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics.

Authors:  Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Annick Chauty; Florence Migot-Nabias; Cyril Badaut; Angèle Bénard; Marie-Therese Ruf; Torsten Seemann; Paul D R Johnson; John K Davies; Grant A Jenkin; Gerd Pluschke; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

8.  Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic.

Authors:  Daniel M N Okenu; Lazarus O Ofielu; Kirk A Easley; Jeannette Guarner; Ellen A Spotts Whitney; Pratima L Raghunathan; Ymkje Stienstra; Kwame Asamoa; Tjip S van der Werf; Winette T A van der Graaf; Jordan W Tappero; David A Ashford; C Harold King
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

9.  Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Authors:  Egídio Torrado; Sarojini Adusumilli; Alexandra G Fraga; Pamela L C Small; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.